H.C. Wainwright analyst Vernon Bernardino initiated coverage with a Buy rating on vTv Therapeutics (VTVT) today and set a price target of $5. The company’s shares closed yesterday at $1.75.
Bernardino said:
“Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows on fully-taxed net income from annual sales and royalty payments of azeliragon and TTP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success.”
According to TipRanks.com, Bernardino has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.3% and a 28.8% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Innovus Pharmaceuticals Inc, Can-Fite BioPharma, and Seres Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for vTv Therapeutics with a $6.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.09 and a one-year low of $0.68. Currently, vTv Therapeutics has an average volume of 750.8K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer.
